ClinicalTrials.gg
CompletedNCT04050670Updated May 6, 2023Results posted

A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

A Phase 1 interventional study of Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females of nonchildbearing potential as determined by medical history, physical examination, and other screening procedures
  • Are between the (BMI) of 18.5 and 45.0 kilograms per meter squared (kg/m²), inclusive, at screening
  • Are agreeable to receiving study treatment by injections under the skin

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to tirzepatide or related compounds
  • Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis), elevation in serum amylase or lipase or gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors
  • Have a prior history of malignant disease(s) in the past 5 years prior to screening
  • Smoke more than the equivalent of 10 cigarettes per day
  • Is a known user of drugs of abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Tirzepatide - Upper Arm

    Participants received 5mg Tirzepatide by subcutaneous injection on upper arm.

    Drug: Tirzepatide

  • Experimental
    Tirzepatide - Thigh

    Participants received 5mg Tirzepatide by subcutaneous injection on thigh.

    Drug: Tirzepatide

  • Active comparator
    Tirzepatide - Abdomen

    Participants received 5mg Tirzepatide by subcutaneous injection on abdomen.

    Drug: Tirzepatide

Interventions

  • Tirzepatide administered SC

    Also known as: LY3298176

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞])

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC\[0-∞\]) was evaluated.

    Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose

  2. PK: Maximum Concentration (Cmax) of Tirzepatide

    PK: Maximum Concentration (Cmax) of Tirzepatide was evaluated.

    Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose

07

Results

Posted Mar 24, 2023

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1Sequence 2Sequence 3
Started181818
Received at least one dose of study drug181818
Completed181818
Not completed000
Period 2
Participant flow — Period 2
MilestoneSequence 1Sequence 2Sequence 3
Started181818
Received at least one dose181818
Completed181818
Not completed000
Period 3
Participant flow — Period 3
MilestoneSequence 1Sequence 2Sequence 3
Started181818
Received at least one dose181718
Completed181718
Not completed010
Withdrew: Physician decision010

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞])

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC\[0-∞\]) was evaluated.

Time frame:
Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose
Reported as:
Geometric mean · Hour * nanogram per milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞])
Hour * nanogram per milliliter (h*ng/mL)Tirzepatide - AbdomenTirzepatide - Upper ArmTirzepatide - Thigh
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of Tirzepatide From Time Zero to Infinity (AUC[0-∞])112000 ± 24111000 ± 21106000 ± 22
Statistical analysis
  • Tirzepatide - Abdomen vs Tirzepatide - Thigh · Linear mixed effects model · Ratio of geometric least squares mean: 0.953 · 90% CI 0.935 to 0.970
  • Tirzepatide - Abdomen vs Tirzepatide - Upper Arm · Linear mixed effects model · Ratio of geometric least squares mean: 0.990 · 90% CI 0.972 to 1.01
PrimaryPK: Maximum Concentration (Cmax) of Tirzepatide

PK: Maximum Concentration (Cmax) of Tirzepatide was evaluated.

Time frame:
Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, 480 hours post dose
Reported as:
Geometric mean · Nanogram per Millilitre (ng/mL)
PK: Maximum Concentration (Cmax) of Tirzepatide
Nanogram per Millilitre (ng/mL)Tirzepatide - AbdomenTirzepatide - Upper ArmTirzepatide - Thigh
PK: Maximum Concentration (Cmax) of Tirzepatide603 ± 25556 ± 23520 ± 21
Statistical analysis
  • Tirzepatide - Abdomen vs Tirzepatide - Thigh · Linear mixed effects model · Ratio of geometric least squares mean: 0.862 · 90% CI 0.818 to 0.909
  • Tirzepatide - Abdomen vs Tirzepatide - Upper Arm · Linear mixed effects model · Ratio of geometric least squares mean: 0.921 · 95% CI 0.874 to 0.971

Adverse events

Collected over Up to 36 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide - Abdomen0/54 (0%)0/54 (0%)37/54 (68.5%)
Tirzepatide - Upper Arm0/54 (0%)0/54 (0%)31/54 (57.4%)
Tirzepatide - Thigh0/53 (0%)0/53 (0%)23/53 (43.4%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTirzepatide - AbdomenTirzepatide - Upper ArmTirzepatide - Thigh
NauseaGastrointestinal disorders20/5412/5411/53
Decreased appetiteMetabolism and nutrition disorders13/547/543/53
HeadacheNervous system disorders12/548/546/53
DyspepsiaGastrointestinal disorders10/5411/546/53
Abdominal distensionGastrointestinal disorders8/5410/548/53
VomitingGastrointestinal disorders9/5410/544/53
ConstipationGastrointestinal disorders4/542/542/53
EructationGastrointestinal disorders3/544/541/53
Early satietyGeneral disorders2/540/543/53
DiarrhoeaGastrointestinal disorders3/542/541/53

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean47.1 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female17
Male37
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino16
Not Hispanic or Latino38
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American14
White40
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States54
08

Study locations

1 site
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Apr 2020, 6 months.

Results were first posted in Mar 2023, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2019
First posted
Aug 8, 2019
StartActual
Sep 13, 2019
Primary completionActual
Apr 3, 2020
CompletionActual
Apr 3, 2020
Results first posted
Mar 24, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04050670
Responsible party
Sponsor
First posted
Aug 8, 2019
Start date
Sep 13, 2019
Primary completion
Apr 3, 2020
Completion
Apr 3, 2020
Results posted
Mar 24, 2023
Last update
May 6, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion